A 64-year-old man presented for outpatient evaluation of multiple cutaneous skin lesions that began as erythematous macules approximately 1 year earlier and progressed to areas of brownish hyperpigmentation. Review of systems was signifi cant for fever, night sweats, fatigue, and epistaxis. Physical examination demonstrated bilateral inguinal lymphadenopathy. Bone marrow and lymph node biopsies were subsequently performed and demonstrated evidence of blastic plasmacytoid dendritic cell neoplasm. Baseline 18-fl uoro-2-deoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) showed FDG uptake within enlarged left iliac and bilateral inguinal lymph nodes, as well as moderate splenomegaly.
Pulmonary mucormycosis complicating cutaneous blastic plasmacytoid dendritic cell neoplasm
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Th e patient received one cycle of the EPOCH regimen (etoposide, vincristine, doxorubicin, cyclophosphamide, and prednisone) and three cycles of hyperCVAD (course A, cyclophosphamide, vincristine, doxorubicin, and dexamethasone; course B, methotrexate and cytarabine). He initially tolerated chemotherapy without evidence of toxicity or opportunistic infection. A posteroanterior chest radiograph obtained following treatment demonstrated an irregular opacity in the left upper lung zone (Figure 1 ). Subsequent contrast-enhanced chest CT showed an irregular opacity in the anterior segment of the left upper lobe consisting of central ground-glass opacity surrounded by consolidation in a "reversed halo" confi guration (Figure 2 ). Follow-up PET/CT showed intense FDG uptake within the region of consolidation, but only minimal FDG uptake within the central ground-glass opacity (Figure 3) .
Bronchoscopy and bronchoalveolar lavage demonstrated one colony of fungal organisms from the genus Paecilomyces, and a regimen of Augmentin and voriconazole was initiated. A left upper lobectomy through video-assisted thoracoscopic surgery was subsequently performed and showed fungal organisms of the order Mucorales. Augmentin was discontinued, and antifungal therapy was modifi ed to amphotericin B and posaconazole.
DIAGNOSIS: Pulmonary mucormycosis.
DISCUSSION
Mucormycosis is an infection by fungal organisms from the class Zygomycetes, most commonly those within the order Mucorales. Six clinical syndromes of mucormycosis have been described, including rhinocerebral, pulmonary, abdominopelvic, cutaneous, disseminated, and miscellaneous forms. Pulmonary infection is the second most common clinical syndrome, accounting for approximately 30% of cases of mucormycosis (1) .
Th e most common symptoms at the time of presentation include fever, cough, dyspnea, chest pain, and hemoptysis. Risk factors for the development of mucormycosis include immunosuppression, hematologic malignancies, solid organ and stem cell transplantation, graft-versus-host disease, diabetes mellitus, chronic renal failure, treatment with deferoxamine, and severe burn injuries (2) . Pathology specimens typically demonstrate broad and irregular hyphae and random branching at right angles. Additional fi ndings such as vascular invasion, thrombosis, and necrosis may be present (3) .
Treatment of pulmonary mucormycosis may include medical and/or surgical therapies. Medical therapy primarily involves amphotericin B and posaconazole. Although eff ective in the treatment of aspergillosis, voriconazole is not eff ective in the treatment of mucormycosis (4) . Surgical therapy, such as wedge resection, lobectomy, and pneumonectomy, in combination with medical therapy, has been associated with lower mortality rates. When fatal, the most common causes of death include fungal sepsis, respiratory failure, and hemoptysis (5) .
Th e most common fi nding on chest radiographs in patients with pulmonary mucormycosis is segmental or lobar consolidation, which may progress to involve multiple lobes over time. Consolidation, which may represent pneumonia, hemorrhage, or infarction, may also involve multiple lobes at the time of initial presentation. Solitary or multiple pulmonary nodules or masses, with or without cavitation, may also be present. Pleural eff usions have been described. Chest CT typically confi rms these fi ndings and may demonstrate additional fi ndings not discernible on chest radiography. Th e air-crescent sign, characterized by a crescentic collection of air interposed between the lung parenchyma and centrally necrotic lung, may be present in the setting of invasive mucormycosis but is seen less frequently than in invasive aspergillosis. Th e CT halo sign, seen as central consolidation surrounded by ground-glass opacity, may be present (6) . Th e reversed halo sign, characterized by central ground-glass opacity surrounded by consolidation, has also been reported in cases of pulmonary mucormycosis. Although initially described in cryptogenic organizing pneumonia, this radiologic sign has also been described in other causes of pulmonary infection such as bacterial pneumonia, tuberculosis, aspergillosis, and paracoccidioidomycosis, as well as other entities such as Wegener granulomatosis, sarcoidosis, lymphomatoid granulomatosis, and pulmonary infarction (7, 8) . Additional fi ndings such as ground-glass opacities in the lung parenchyma, endobronchial lesions, and chest wall lesions may also be identifi ed on CT (6). 
